23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Nordic
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Orexo CEO on settlement: “Very mixed feelings”

After more than $14m in legal fees and years of uncertainty, Orexo is closing in on a settlement with the US Department of Justice.
Advertisement

The US Department of Justice (DOJ) has been investigating Orexo’s former sales and marketing practices for its opioid dependence drug Zubsolv in the US since 2020.

Now, the lengthy process may be nearing its end. On Monday, the Uppsala-based company announced that it had reached a non-binding agreement in principle with the DOJ on a settlement.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.031|